Kuros Biosciences AG (CSBTF PINK) stock market data APIs
$21.4
0(0%)
as of January 24, 2025
Kuros Biosciences AG Financial Data Overview
Price chart is built with
Anychart
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft. Its Fibrin-PTH pipeline products comprise KUR-111 and KUR-113 that are in Phase 2b clinical trials for trauma indications; KUR-113 that is in Phase 2a clinical trial for spinal indications. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
Prev. Close
21.4
Open
21.4
Volume
25
High
21.4
Low
21.4
52 wk Range
5.4-36.1
Market Cap
889 M
Shares Outstanding
37 735 K
Revenue
52 542 K
EPS
-0.0016
Beta
0.758
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kuros Biosciences AG data using free add-ons & libraries
Get Kuros Biosciences AG Fundamental Data
Kuros Biosciences AG Fundamental data includes:
- Net Revenue: 52 542 K
- EBITDA: -3 050 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kuros Biosciences AG News
New
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
Kuros Biosciences Ad-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Swit...
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals
Ad hoc announcement pursuant to Article 53 of the SIX listing rules SCHLIEREN (ZURICH), Switzerland, July 15, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” or the “Company”), a leade...
Kuros Biosciences’s licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ
Total gross proceeds raised by Checkmate in IPO of $86.25 million (including sale of overallotment shares) Intention to use part of the net proceeds from the IPO to fund the development of its product...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
